ayala
pharmaceuticals
participate
upcoming
virtual
investor
conferences
rehovot
israel
wilmington
globe
newswire
ayala
pharmaceuticals
nasdaq
ayla
oncology
company
focused
developing
commercializing
small
molecule
therapeutics
patients
suffering
rare
aggressive
cancers
primarily
genetically
defined
patient
populations
today
announced
ayala
management
participate
two
upcoming
virtual
investor
conferences
wainwright
th
annual
israel
conference
thursday
november
et
annual
israel
conference
thursday
november
et
jefferies
virtual
london
healthcare
conference
fireside
chat
thursday
november
pm
et
live
webcast
event
may
accessed
visiting
events
presentations
section
ayala
website
archived
replay
webcast
available
website
days
following
presentations
ayala
pharmaceuticals
ayala
pharmaceuticals
oncology
company
focused
developing
commercializing
small
molecule
therapeutics
patients
suffering
rare
aggressive
cancers
primarily
genetically
defined
patient
populations
ayala
approach
focused
predicating
identifying
addressing
tumorigenic
drivers
cancer
combination
bioinformatics
platform
sequencing
deliver
targeted
therapies
underserved
patient
populations
company
two
product
candidates
development
targeting
aberrant
activation
notch
pathway
gamma
secretase
inhibitors
treat
variety
tumors
including
adenoid
cystic
carcinoma
triple
negative
breast
cancer
tnbc
acute
lymphoblastic
leukemia
desmoid
tumors
multiple
myeloma
mm
collaboration
novartis
ayala
lead
product
candidate
received
fast
track
designation
orphan
drug
designation
fda
currently
phase
clinical
trial
patients
acc
accuracy
bearing
notch
activating
mutations
phase
clinical
trial
patients
tnbc
tenacity
bearing
notch
activating
mutations
gene
rearrangements
information
visit
contacts
investors
julie
seidel
stern
investor
relations
ayala
pharmaceuticals
info
